Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
381-400 of 604 trials

Efgartigimod for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will evaluate the safety, dosing, and effects of this treatment on their daily lives.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Chronic Rhinosinusitis with Nasal Polyps: Tezepelumab Study

We are investigating how tezepelumab affects symptoms in adults with chronic rhinosinusitis and nasal polyps. The study looks at changes in nasal congestion, sense of smell, and overall quality of life.

Chronic Rhinosinusitis with Nasal Polyps3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Hypertrophic Cardiomyopathy: Sotagliflozin Study

We are investigating whether sotagliflozin can improve symptoms in people with hypertrophic cardiomyopathy. The study also looks at the safety of this treatment compared to a placebo.

Hypertrophic Cardiomyopathy6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Pancreatic Cancer: TCR-Modified T-Cell Therapy

We are studying a new therapy using modified T-cells for adults with advanced pancreatic cancer that has specific genetic mutations. The trial aims to assess safety and how well this treatment may work.

Pancreatic Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Heart Failure and Kidney Disease: SENEKA Study

We are exploring a new treatment strategy for elderly patients with heart failure and chronic kidney disease to see if it helps manage potassium levels better. This study compares a potassium binder with standard medications to improve patient outcomes.

Chronic Heart Failure and Non-Dialysis Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal MedicineNephrology

Influenza Vaccination: Antibody Responses Study

We are investigating how intranasal and intramuscular flu vaccines affect antibody levels in the nose. This research may help improve future vaccination methods.

Healthy Participants≤3 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

GIST Treatment: Lenvatinib vs. Placebo

We are evaluating whether lenvatinib can help patients with advanced GIST who did not respond to imatinib and sunitinib. This study compares its effects to a placebo to assess its potential benefits.

Metastatic Gastrointestinal Stromal Tumor (GIST)>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesOncology

Venous Thromboembolism in Cancer: Abelacimab vs. Dalteparin

We are studying whether a new medication, abelacimab, can effectively prevent blood clots in patients with gastrointestinal or genitourinary cancer. This trial compares it to the standard treatment, dalteparin.

Venous Thromboembolism (VTE)6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Vibegron for Children with Neurogenic Detrusor Overactivity

We are studying the safety and effectiveness of vibegron in children aged 2 to under 18 with neurogenic detrusor overactivity who use clean intermittent catheterization. This trial aims to understand how well the medication works and how it is processed in young patients.

Neurogenic Bladder1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPediatricsUrology

Colorectal Cancer: New Immunotherapy Treatment

We are studying a combination of Pembrolizumab and a Dendritic Cell Vaccine, followed by other medications, for patients with advanced colorectal cancer that hasn't responded to prior treatments. The goal is to see if this approach improves survival and safety.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

PD-1 Antibody for Metastatic Solid Tumors

We are testing a new method of delivering a PD-1 antibody directly into the spinal fluid for patients with metastatic solid tumors and leptomeningeal disease. The study aims to determine the safe dosage and its potential impact on survival.

Leptomeningeal Disease6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Mesothelioma: Talazoparib Maintenance Treatment

We are studying whether talazoparib can help keep mesothelioma from progressing after initial chemotherapy. This trial is for patients with advanced pleural or peritoneal mesothelioma.

Advanced Malignant Mesothelioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Heart Failure: Vericiguat Study

We are studying the effects of vericiguat in patients with heart failure and reduced ejection fraction. The goal is to see if it can lower heart failure markers compared to a placebo.

Heart Failure with Reduced Ejection Fraction (HFrEF)3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Atrial Fibrillation: Amiodarone Dose Comparison

We are studying whether a standard or reduced dose of amiodarone is more effective in keeping a normal heart rhythm after cardioversion in patients with persistent atrial fibrillation. We will also assess any side effects and how genetics may affect treatment.

Persistent Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyInternal Medicine

Navepegritide for Growth in Adolescents with Achondroplasia

We are studying whether navepegritide can help improve growth in adolescents aged 12 to under 18 with achondroplasia. This trial will help us understand its effectiveness and safety.

Achondroplasia1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Primary Sclerosing Cholangitis: Norucholic Acid Tablets

We are studying the safety and tolerability of norucholic acid tablets for people with primary sclerosing cholangitis. We also want to see if it effectively helps manage their condition.

Primary Sclerosing Cholangitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyHepatology

PRCA Treatment: Isatuximab Study

We are studying whether the drug isatuximab can help patients with pure red cell aplasia after stem cell transplantation. This trial compares its effects to standard supportive care to see which is more effective.

Pure Red Cell Aplasia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Short-Term Insomnia: Neurexan® Treatment

We are exploring whether Neurexan® can improve sleep quality and daytime performance in people with short-term insomnia. This study compares its effects to a placebo to understand its potential benefits.

Short-Term Insomnia>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteNeurologyPsychiatry

Neovascular AMD: Faricimab Treatment Study

We are exploring whether two initial doses of faricimab can help keep neovascular AMD inactive in treatment-naive patients. The study also looks at factors that may predict disease activity and recurrence.

Age-related Macular Degeneration>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesOphthalmology

Fibrotic Lung Disease: Wharton's Jelly Stem Cells

We are studying the safety and effects of a stem cell treatment for people with fibrotic interstitial lung diseases. This research aims to see if it can improve lung function and quality of life.

Interstitial Lung Disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicinePulmonology